AR040048A1 - Derivados de 1-(aminoalquil)-3-sulfonilindol e indazol como ligandos de la 5-hidroxitriptamina-6 - Google Patents

Derivados de 1-(aminoalquil)-3-sulfonilindol e indazol como ligandos de la 5-hidroxitriptamina-6

Info

Publication number
AR040048A1
AR040048A1 ARP030101812A ARP030101812A AR040048A1 AR 040048 A1 AR040048 A1 AR 040048A1 AR P030101812 A ARP030101812 A AR P030101812A AR P030101812 A ARP030101812 A AR P030101812A AR 040048 A1 AR040048 A1 AR 040048A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
cycloalkyl
aryl
independently
alkyl
Prior art date
Application number
ARP030101812A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR040048A1 publication Critical patent/AR040048A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Abstract

Reivindicación 1: Un compuesto de la fórmula (1) en la cual W es N o CR2; R es H, halógeno, CN, OCO2R7, CO2R8, CONR9R10, SOpR11, NR12R13, OR14, COR15 o un alquilo de C1-6, un alquenilo de C2-6, un alquinilo de C2-6, un cicloalquilo de C3-7, un grupo cicloheteroalquilo, arilo o heteroarilo, cada uno sustituido opcionalmente; R1 es un grupo alquilo de C1-6, cicloalquilo de C3-7, arilo o heteroarilo opcionalmente sustituidos o un sistema de anillos opcionalmente sustituido de 8 a 13 miembros bicíclico o tricíclico que tiene un átomo de N en la cabeza de puente y que contiene en forma opcional 1, 2 o 3 heteroátomos adicionales seleccionados de N, O o S; R2 es H, halógeno, o un grupo alquilo de C1-6, alcoxi de C1-6, cicloalquilo de C3-7, arilo o heteroarilo, cada uno opcionalmente sustituido; R3 y R4 son cada uno en forma independiente H, o un grupo alquilo de C1-6 opcionalmente sustituido; R5 y R6 son cada uno en forma independiente H o un grupo alquilo de C1-6, alquenilo de C2-6, alquinilo de C2-6, cicloalquilo de C3-7, cicloheteroalquilo, arilo o heteroarilo, cada uno opcionalmente sustituido o R5 y R6 se pueden tomar junto con el átomo al cual están unidos para formar un anillo opcionalmente sustituido de 5 a 8 miembros que contiene en forma opcional un heteroátomo adicional elegido de O, NR16 o SOx; m es 0 o un entero de valor 1, 2 o 3; n es un entero de valor 2, 3, 4 o 5; p y x son cada uno en forma independiente 0 o un entero de valor 1 o 2; R7, R8, R11, R15 y R16 son cada uno en forma independiente H o un grupo alquilo de C1-6, alquenilo de C2-6, alquinilo de C2-6, cicloalquilo de C3-6, cicloheteroalquilo, arilo o heteroarilo, cada uno opcionalmente sustituido; R9 y R10 son cada uno en forma independiente H o un grupo alquilo de C1-6 o cicloalquilo de C3-7, cada uno opcionalmente sustituido o R9 y R10 se pueden tomar juntos con el átomo al cual están unidos para formar un anillo de 5 a 7 miembros que contiene en forma opcional otro heteroátomo elegido de O, NR18 o S; R12 y R13 son cada uno en forma independiente H o un grupo alquilo de C1-4 opcionalmente sustituido o R12 y R13 se pueden tomar juntos con el átomo al cual están unidos para formar un anillo de 5 a 7 miembros que contiene en forma opcional otro heteroátomo elegido de O, NR17 o SOq; R14 es un grupo alquilo de C1-6, alquenilo de C2-6, alquinilo de C2-6, cicloalquilo de C3-7, cicloheteroalquilo, arilo o heteroarilo, cada uno opcionalmente sustituido; q es 0 o un entero de valor 1 o 2; y R17 y R18 so cada uno en forma independiente H o un grupo alquilo de C1-6, alquenilo de C2-6, alquinilo de C2-6, cicloalquilo de C3-7, cicloheteroalquilo, arilo o heteroarilo, cada uno opcionalmente sustituido, o un estereoisómero del mismo o una sal aceptable para uso farmacéutico del mismo.
ARP030101812A 2002-06-04 2003-05-23 Derivados de 1-(aminoalquil)-3-sulfonilindol e indazol como ligandos de la 5-hidroxitriptamina-6 AR040048A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38569502P 2002-06-04 2002-06-04

Publications (1)

Publication Number Publication Date
AR040048A1 true AR040048A1 (es) 2005-03-09

Family

ID=29712202

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101812A AR040048A1 (es) 2002-06-04 2003-05-23 Derivados de 1-(aminoalquil)-3-sulfonilindol e indazol como ligandos de la 5-hidroxitriptamina-6

Country Status (21)

Country Link
US (1) US6727246B2 (es)
EP (1) EP1509501B1 (es)
JP (1) JP2005536473A (es)
CN (1) CN1656069A (es)
AR (1) AR040048A1 (es)
AT (1) ATE348806T1 (es)
AU (1) AU2003237355A1 (es)
BR (1) BR0311436A (es)
CA (1) CA2485871A1 (es)
CR (1) CR7566A (es)
DE (1) DE60310552T2 (es)
DK (1) DK1509501T3 (es)
EC (1) ECSP045473A (es)
ES (1) ES2279125T3 (es)
MX (1) MXPA04011315A (es)
NO (1) NO20044764L (es)
NZ (1) NZ536921A (es)
RU (1) RU2004139099A (es)
TW (1) TW200400177A (es)
WO (1) WO2003101962A1 (es)
ZA (1) ZA200500021B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL370342A1 (en) * 2001-09-27 2005-05-16 F.Hoffmann-La Roche Ag Indole derivatives as cox ii inhibitors
KR20040085179A (ko) * 2002-02-13 2004-10-07 코닌클리케 필립스 일렉트로닉스 엔.브이. 통합된 반도체 광학 디바이스, 이러한 디바이스를제조하는 방법 및 장치
TW200401641A (en) * 2002-07-18 2004-02-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands
WO2004074243A2 (en) * 2003-02-14 2004-09-02 Wyeth Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
EP1647549A1 (en) * 2004-10-14 2006-04-19 Laboratoire Theramex Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents
AR054394A1 (es) * 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de 2- (1h-indolilsulfanil)-aril amina
EP1899340A4 (en) * 2005-06-28 2009-09-16 Merck & Co Inc NON-NUCLEOSIDIC REVERSE TRANSCRIPTASE INHIBITORS
CA2612592A1 (en) * 2005-06-28 2007-01-04 Merck & Co., Inc. Non-nucleoside reverse transcriptase inhibitors
AU2006261954A1 (en) * 2005-06-28 2007-01-04 Merck & Co., Inc. Non-nucleoside reverse transcriptase inhibitors
RU2429231C2 (ru) * 2005-08-15 2011-09-20 Вайет Производные замещенного-3-сульфонилиндазола в качестве лигандов 5-гидрокситриптамина-6
MX2008002158A (es) * 2005-08-15 2008-04-19 Wyeth Corp Derivados de azinil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6.
WO2007053353A2 (en) * 2005-10-28 2007-05-10 Wyeth Pyrrolo[2,3-f] and [3,2-f]isoquinolinone derivatives as 5-hydroxytryptamine-6 ligands
WO2007117413A1 (en) * 2006-04-05 2007-10-18 Wyeth Sulfonyl-3-heterocyclylindazole derivatives as 5-hydroxytryptamine-6 ligands
WO2007120596A1 (en) * 2006-04-12 2007-10-25 Wyeth DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
AU2008256859A1 (en) * 2007-05-24 2008-12-04 Memory Pharmaceuticals Corporation 4' substituted compounds having 5-HT6 receptor affinity
US20090012308A1 (en) * 2007-06-13 2009-01-08 Wyeth Process for the manufacture of benzylsulfonylarenes
US20100016297A1 (en) * 2008-06-24 2010-01-21 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
US20100022581A1 (en) * 2008-07-02 2010-01-28 Memory Pharmaceuticals Corporation Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity
US20100029629A1 (en) * 2008-07-25 2010-02-04 Memory Pharmaceuticals Corporation Acyclic compounds having 5-ht6 receptor affinity
US20100056531A1 (en) * 2008-08-22 2010-03-04 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
KR20150032329A (ko) * 2012-07-10 2015-03-25 에프. 호프만-라 로슈 아게 호흡기 세포융합 바이러스 감염의 치료 및 예방을 위한 신규한 인다졸
WO2018064094A1 (en) 2016-09-28 2018-04-05 Bristol-Myers Squibb Company Enantioselective synthesis of pyrroloindole compounds
WO2018165501A1 (en) * 2017-03-10 2018-09-13 Lycera Corporation INDOLINYL SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATMENT OF DISEASE
CN111269165A (zh) * 2018-12-05 2020-06-12 中国科学院大连化学物理研究所 一种3-芳基磺酰基吲哚衍生物的合成方法
SG11202109111VA (en) 2019-02-27 2021-09-29 Univ California Azepino-indoles and other heterocycles for treating brain disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4654360A (en) 1984-06-01 1987-03-31 Syntex (U.S.A.) Inc. 1,2,3-trisubstituted indoles for treatment of inflammation
FR2642755B1 (es) 1989-02-07 1993-11-05 Sanofi
US5132319A (en) 1991-03-28 1992-07-21 Merck Frosst Canada, Inc. 1-(hydroxylaminoalkyl) indole derivatives as inhibitors of leukotriene biosynthesis
US6100291A (en) * 1998-03-16 2000-08-08 Allelix Biopharmaceuticals Inc. Pyrrolidine-indole compounds having 5-HT6 affinity
UA59443C2 (uk) 1998-04-28 2003-09-15 Арцнайміттельверк Дрезден Гмбх Гідроксііндол, спосіб його одержання, лікарська форма на його основі та спосіб її одержання
GB9819032D0 (en) * 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds IV
GB9820113D0 (en) 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
EP1276720B1 (de) 2000-04-28 2006-12-20 Baxter Healthcare S.A. 2-acyl-indolderivate und deren verwendung als antitumormittel
JP4187642B2 (ja) * 2001-06-07 2008-11-26 エフ.ホフマン−ラ ロシュ アーゲー 5−ht6受容体親和性を有する新規インドール誘導体

Also Published As

Publication number Publication date
EP1509501B1 (en) 2006-12-20
CA2485871A1 (en) 2003-12-11
NZ536921A (en) 2006-06-30
CN1656069A (zh) 2005-08-17
ATE348806T1 (de) 2007-01-15
AU2003237355A1 (en) 2003-12-19
DE60310552D1 (de) 2007-02-01
ECSP045473A (es) 2005-01-28
NO20044764L (no) 2005-01-03
RU2004139099A (ru) 2005-06-10
ES2279125T3 (es) 2007-08-16
WO2003101962A1 (en) 2003-12-11
JP2005536473A (ja) 2005-12-02
US20030232828A1 (en) 2003-12-18
ZA200500021B (en) 2006-06-28
MXPA04011315A (es) 2005-02-14
CR7566A (es) 2005-01-05
DE60310552T2 (de) 2007-09-27
TW200400177A (en) 2004-01-01
BR0311436A (pt) 2005-03-22
US6727246B2 (en) 2004-04-27
DK1509501T3 (da) 2007-03-12
EP1509501A1 (en) 2005-03-02

Similar Documents

Publication Publication Date Title
AR040048A1 (es) Derivados de 1-(aminoalquil)-3-sulfonilindol e indazol como ligandos de la 5-hidroxitriptamina-6
AR040567A1 (es) Derivados de 1- heterociclilalquil 3- sulfonilindol o -indazol como ligandos de 5- hidroxitriptamina -6
AR040047A1 (es) 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de la 5-hidroxitriptamina-6
AR040566A1 (es) Derivados de 1-heterociclilalquil 3- sulfonilazaindol o azaindazol como ligandos de 5 hidroxitriptamina-6
AR043180A1 (es) Derivados de heterociclil-3-sulfonilazaindol o -azaindazol como ligandos de 5-hidroxitriptamina-6
CO5650164A2 (es) Hetrociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
AR037906A1 (es) Derivados de indolilalquilamina como ligandos de 5-hidroxitriptamina-6
AR064345A1 (es) Derivados de 8-oxoadenina
AR052943A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
AR043938A1 (es) Compuesto heterociclico derivado de quinolina o naftiridina, composicion farmaceutica que lo comprende y su uso para preparar esta ultima
AR038703A1 (es) Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3
AR057380A1 (es) Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos
AR061923A1 (es) Compuestos derivados de benzofuran-piperidina
AR069691A1 (es) Derivados ciclopropilamina
AR055401A1 (es) Derivados de benzotiazolona
ES2393824T3 (es) Derivados de piridin-2-il-amino-1,2,4-tiadiazol como activadores de glucoquinasa para el tratamiento de diabetes mellitus
AR052458A1 (es) Amino-imidazolonas para la inhibicion de beta-secretasa
AR054090A1 (es) Derivados de quinuclidina como antagonistas del receptor muscarinico m3. composiciones farmaceuticas y proceso de obtencion
AR056536A1 (es) Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace)
AR075605A1 (es) Derivados de imidazolilpirazina
AR070343A1 (es) Piridinil amidas, un procedimiento para el tratamiento de la esquizofrenia en un mamifero y una composicion farmaceutica
PE20130306A1 (es) Morfolinopirimidinas y su uso en terapia
AR061026A1 (es) Compuesto glicitol c-fenilo y preparacion farmaceutica
AR070992A1 (es) Derivados de 2-aril-6-fenil-inidazo[1,2a]piridinas, su preparacion, composiciones farmaceuticas y su uso en enfermedades que implican los receptores nucleares nurr-1

Legal Events

Date Code Title Description
FB Suspension of granting procedure